Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Androgen Receptor Signaling and PSMA Expression in Prostate Cancer
NCT05683964Phase 1Active, not recruiting
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jan 2023
- Primary completion
- Sep 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of apalutamide, darolutamide and enzalutamide in prostate cancer (PCa), sponsored by Beth Israel Deaconess Medical Center. Primary endpoint: Proportion of Participants with New Lesions (Flare) at 4 weeks. Started Jan 2023; status: active, not recruiting.
02
Drugs
apalutamidedarolutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05683964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683964.